Refine by
Vascular Tissue Articles & Analysis
14 news found
These new Circulatory System Tissue Microarrays, including Heart & Vascular Tissue Microarrays and Spleen Tissue Microarrays, are designed to accelerate research into heart disease, vascular disorders, and other conditions affecting the circulatory system. ...
In fact, in spite of the very low temperature reached, -10°C, and kept constant during the 50 minutes of treatment, the vascularization and the tonicity of the tissues of the treated area are preserved, as well as the cellular structures and their functionality. ...
HyStem is a patented hydrogel which mimics naturally occurring extracellular matrix, the structural network of molecules surrounding cells in organs and tissues and essential to cellular function and tissue structure. HyStem biomaterial has been shown to support cellular attachment and survival as well as compatibility with a wide variety of cells and ...
About SANUWAVE Health SANUWAVE Health (OTCQB: SNWV) is focused on the research, development, and commercialization of its patented, Energy First non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE's end-to-end wound care portfolio of regenerative ...
These latest imaging biomarkers strengthen VIDA’s portfolio of airway, tissue, vascular and functional measures. VIDA’s latest airway biomarkers include mucus plug scoring, bronchiectasis scoring, and total airway count (TAC). ...
The patent has 20 claims and will expire on November 14, 2037. EP 3285661 titled "Tissue Disinfection with Acoustic Pressure Shock Waves", with the United Kingdom, France, Germany, and Netherland as designated countries. This patent covers the methods and device embodiments that use extracorporeal acoustic pressure shock waves for preventing and treating living ...
” About SANUWAVE SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and ...
” About SANUWAVE SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and ...
The main objective of the study was to observe the effects of dermaPACE System's focused shockwaves on tissue oxygen saturation within the wound bed as measured using near-infrared spectroscopy. ...
(OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, today announced its rebranding. The new brand reflects the evolution of SANUWAVE’s solutions addressing the entire wound care pathway through its portfolio of noninvasive and ...
(OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, announced today that the Company has entered into a non-exclusive sales and marketing agreement with Ametus to market and sell the Company’s portfolio of wound care products in the ...
This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary microfluidic 3D bioprinting platform with JSR’s advanced materials technology to develop implantable vascularized tissues for kidney regeneration and other applications in regenerative medicine. The ...
In conjunction with its formation, Colibri has granted Colorado Therapeutics a license to develop and market innovative and disruptive xenogenic (sourced from different mammalian species) biologic tissue matrix products for a broad range of soft tissue reinforcement, regenerative, and vascular applications outside of structural heart. Colorado ...
In conjunction with its formation, Colibri has granted Colorado Therapeutics a license to develop and market innovative and disruptive xenogenic (sourced from different mammalian species) biologic tissue matrix products for a broad range of soft tissue reinforcement, regenerative, and vascular applications outside of structural heart. Colorado ...